nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—P-Glycoprotein Inhibitors—Vemurafenib—melanoma	0.325	1	CiPCiCtD
Crizotinib—lung cancer—melanoma	0.267	1	CtDrD
Crizotinib—ROS1—melanoma	0.0693	0.27	CbGaD
Crizotinib—EPHA2—melanoma	0.0634	0.247	CbGaD
Crizotinib—PTK2B—melanoma	0.0447	0.174	CbGaD
Crizotinib—AURKA—melanoma	0.038	0.148	CbGaD
Crizotinib—MET—melanoma	0.0372	0.145	CbGaD
Crizotinib—ABCB1—melanoma	0.00434	0.0169	CbGaD
Crizotinib—Electrocardiogram QT corrected interval prolonged—Vemurafenib—melanoma	0.00147	0.0447	CcSEcCtD
Crizotinib—ACVR1—pes—melanoma	0.00144	0.0421	CbGeAlD
Crizotinib—Disease progression—Carmustine—melanoma	0.000957	0.0291	CcSEcCtD
Crizotinib—Electrocardiogram QT prolonged—Vemurafenib—melanoma	0.000615	0.0187	CcSEcCtD
Crizotinib—Periorbital oedema—Bleomycin—melanoma	0.000606	0.0184	CcSEcCtD
Crizotinib—RPS6KB1—leg—melanoma	0.000593	0.0173	CbGeAlD
Crizotinib—CASK—hair follicle—melanoma	0.00053	0.0155	CbGeAlD
Crizotinib—RPS6KB1—hindlimb—melanoma	0.000529	0.0155	CbGeAlD
Crizotinib—IGF1R—skin epidermis—melanoma	0.000529	0.0155	CbGeAlD
Crizotinib—Acute respiratory distress syndrome—Docetaxel—melanoma	0.000514	0.0157	CcSEcCtD
Crizotinib—Gastrointestinal perforation—Docetaxel—melanoma	0.000514	0.0157	CcSEcCtD
Crizotinib—Hepatotoxicity—Vemurafenib—melanoma	0.000512	0.0156	CcSEcCtD
Crizotinib—Gamma-glutamyltransferase increased—Vemurafenib—melanoma	0.00048	0.0146	CcSEcCtD
Crizotinib—RPS6KB1—appendage—melanoma	0.000454	0.0133	CbGeAlD
Crizotinib—MET—blood vessel—melanoma	0.00045	0.0132	CbGeAlD
Crizotinib—Disorder sight—Temozolomide—melanoma	0.000424	0.0129	CcSEcCtD
Crizotinib—Photopsia—Docetaxel—melanoma	0.000422	0.0129	CcSEcCtD
Crizotinib—Polyneuropathy—Docetaxel—melanoma	0.000412	0.0125	CcSEcCtD
Crizotinib—Febrile neutropenia—Bleomycin—melanoma	0.000398	0.0121	CcSEcCtD
Crizotinib—Lymphopenia—Temozolomide—melanoma	0.000395	0.012	CcSEcCtD
Crizotinib—PTK2—skin epidermis—melanoma	0.000393	0.0115	CbGeAlD
Crizotinib—TIE1—endothelium—melanoma	0.000373	0.0109	CbGeAlD
Crizotinib—Febrile neutropenia—Dactinomycin—melanoma	0.000371	0.0113	CcSEcCtD
Crizotinib—STK3—hair follicle—melanoma	0.000367	0.0107	CbGeAlD
Crizotinib—Febrile neutropenia—Carmustine—melanoma	0.000347	0.0106	CcSEcCtD
Crizotinib—TIE1—blood vessel—melanoma	0.000344	0.0101	CbGeAlD
Crizotinib—Transaminases increased—Carmustine—melanoma	0.000343	0.0105	CcSEcCtD
Crizotinib—Visual acuity reduced—Temozolomide—melanoma	0.000339	0.0103	CcSEcCtD
Crizotinib—Interstitial lung disease—Bleomycin—melanoma	0.000338	0.0103	CcSEcCtD
Crizotinib—LIMK2—hair follicle—melanoma	0.000338	0.00986	CbGeAlD
Crizotinib—Febrile neutropenia—Temozolomide—melanoma	0.000336	0.0102	CcSEcCtD
Crizotinib—ACVR1—hair follicle—melanoma	0.000334	0.00976	CbGeAlD
Crizotinib—MET—neck—melanoma	0.000322	0.00941	CbGeAlD
Crizotinib—Dysaesthesia—Docetaxel—melanoma	0.00031	0.00946	CcSEcCtD
Crizotinib—RIPK2—endothelium—melanoma	0.000307	0.00896	CbGeAlD
Crizotinib—Burning sensation—Carmustine—melanoma	0.000301	0.00916	CcSEcCtD
Crizotinib—Interstitial lung disease—Carmustine—melanoma	0.000295	0.00899	CcSEcCtD
Crizotinib—Hepatotoxicity—Dactinomycin—melanoma	0.000289	0.0088	CcSEcCtD
Crizotinib—Interstitial lung disease—Temozolomide—melanoma	0.000285	0.00869	CcSEcCtD
Crizotinib—PTK2—endothelium—melanoma	0.000285	0.00832	CbGeAlD
Crizotinib—RIPK2—blood vessel—melanoma	0.000283	0.00827	CbGeAlD
Crizotinib—TBK1—hair follicle—melanoma	0.00028	0.00818	CbGeAlD
Crizotinib—IRAK1—hair follicle—melanoma	0.000275	0.00802	CbGeAlD
Crizotinib—Hepatotoxicity—Carmustine—melanoma	0.000271	0.00824	CcSEcCtD
Crizotinib—Abscess—Carmustine—melanoma	0.000264	0.00804	CcSEcCtD
Crizotinib—PTK2—blood vessel—melanoma	0.000263	0.00767	CbGeAlD
Crizotinib—Lymphopenia—Docetaxel—melanoma	0.000262	0.00799	CcSEcCtD
Crizotinib—Hepatotoxicity—Temozolomide—melanoma	0.000261	0.00796	CcSEcCtD
Crizotinib—EPHB4—endothelium—melanoma	0.000259	0.00757	CbGeAlD
Crizotinib—MAPK7—retina—melanoma	0.000254	0.00741	CbGeAlD
Crizotinib—EPHA8—eye—melanoma	0.000253	0.0074	CbGeAlD
Crizotinib—IGF1R—neck—melanoma	0.000253	0.0074	CbGeAlD
Crizotinib—ANKK1—head—melanoma	0.000251	0.00732	CbGeAlD
Crizotinib—TEK—endothelium—melanoma	0.000248	0.00725	CbGeAlD
Crizotinib—Gamma-glutamyltransferase increased—Temozolomide—melanoma	0.000245	0.00747	CcSEcCtD
Crizotinib—MAP4K5—hair follicle—melanoma	0.000244	0.00713	CbGeAlD
Crizotinib—MET—eye—melanoma	0.00024	0.007	CbGeAlD
Crizotinib—EPHB4—blood vessel—melanoma	0.000239	0.00698	CbGeAlD
Crizotinib—MET—retina—melanoma	0.000238	0.00694	CbGeAlD
Crizotinib—JAK2—blood vessel—melanoma	0.000237	0.00693	CbGeAlD
Crizotinib—EPHA2—blood vessel—melanoma	0.000235	0.00685	CbGeAlD
Crizotinib—TEK—blood vessel—melanoma	0.000229	0.00668	CbGeAlD
Crizotinib—YES1—hair follicle—melanoma	0.000225	0.00658	CbGeAlD
Crizotinib—Weight decreased—Vemurafenib—melanoma	0.000224	0.00683	CcSEcCtD
Crizotinib—Febrile neutropenia—Docetaxel—melanoma	0.000223	0.0068	CcSEcCtD
Crizotinib—ACVR1B—eye—melanoma	0.000222	0.00647	CbGeAlD
Crizotinib—EPHA3—eye—melanoma	0.000222	0.00647	CbGeAlD
Crizotinib—Infestation NOS—Vemurafenib—melanoma	0.000221	0.00673	CcSEcCtD
Crizotinib—Infestation—Vemurafenib—melanoma	0.000221	0.00673	CcSEcCtD
Crizotinib—SRC—endothelium—melanoma	0.00022	0.00644	CbGeAlD
Crizotinib—EPHA3—retina—melanoma	0.00022	0.00641	CbGeAlD
Crizotinib—Neuropathy peripheral—Vemurafenib—melanoma	0.000217	0.0066	CcSEcCtD
Crizotinib—Gait disturbance—Carmustine—melanoma	0.000214	0.00652	CcSEcCtD
Crizotinib—BMP2K—neck—melanoma	0.000211	0.00617	CbGeAlD
Crizotinib—Pulmonary embolism—Carmustine—melanoma	0.000209	0.00636	CcSEcCtD
Crizotinib—MET—skin of body—melanoma	0.000209	0.00609	CbGeAlD
Crizotinib—Gait disturbance—Temozolomide—melanoma	0.000207	0.0063	CcSEcCtD
Crizotinib—Respiratory failure—Temozolomide—melanoma	0.000206	0.00626	CcSEcCtD
Crizotinib—SRC—blood vessel—melanoma	0.000203	0.00594	CbGeAlD
Crizotinib—MAPK7—mammalian vulva—melanoma	0.000203	0.00593	CbGeAlD
Crizotinib—Phosphatase alkaline increased—Temozolomide—melanoma	0.000202	0.00615	CcSEcCtD
Crizotinib—Pulmonary embolism—Temozolomide—melanoma	0.000202	0.00615	CcSEcCtD
Crizotinib—Neuropathy—Carmustine—melanoma	0.000196	0.00597	CcSEcCtD
Crizotinib—EPHA5—eye—melanoma	0.000196	0.00573	CbGeAlD
Crizotinib—Oedema peripheral—Vemurafenib—melanoma	0.000195	0.00595	CcSEcCtD
Crizotinib—Haemoglobin decreased—Docetaxel—melanoma	0.000195	0.00594	CcSEcCtD
Crizotinib—EPHA5—retina—melanoma	0.000194	0.00568	CbGeAlD
Crizotinib—Sepsis—Dactinomycin—melanoma	0.000194	0.0059	CcSEcCtD
Crizotinib—Burning sensation—Docetaxel—melanoma	0.000193	0.00589	CcSEcCtD
Crizotinib—Neuralgia—Docetaxel—melanoma	0.000193	0.00589	CcSEcCtD
Crizotinib—MAP4K1—retina—melanoma	0.00019	0.00556	CbGeAlD
Crizotinib—Interstitial lung disease—Docetaxel—melanoma	0.00019	0.00578	CcSEcCtD
Crizotinib—Neuropathy—Temozolomide—melanoma	0.00019	0.00577	CcSEcCtD
Crizotinib—IGF1R—eye—melanoma	0.000188	0.0055	CbGeAlD
Crizotinib—TBK1—neck—melanoma	0.000188	0.00549	CbGeAlD
Crizotinib—PTK2—neck—melanoma	0.000188	0.00549	CbGeAlD
Crizotinib—Eye disorder—Vemurafenib—melanoma	0.000185	0.00565	CcSEcCtD
Crizotinib—Cardiac disorder—Vemurafenib—melanoma	0.000184	0.00561	CcSEcCtD
Crizotinib—STK3—eye—melanoma	0.000183	0.00535	CbGeAlD
Crizotinib—Sepsis—Carmustine—melanoma	0.000181	0.00552	CcSEcCtD
Crizotinib—RPS6KB1—neck—melanoma	0.000181	0.00528	CbGeAlD
Crizotinib—Hepatic failure—Dactinomycin—melanoma	0.00018	0.00549	CcSEcCtD
Crizotinib—NEK9—head—melanoma	0.00018	0.00524	CbGeAlD
Crizotinib—Mediastinal disorder—Vemurafenib—melanoma	0.000179	0.00545	CcSEcCtD
Crizotinib—TESK1—eye—melanoma	0.000177	0.00517	CbGeAlD
Crizotinib—IKBKE—lymph node—melanoma	0.000175	0.00512	CbGeAlD
Crizotinib—Hepatotoxicity—Docetaxel—melanoma	0.000174	0.0053	CcSEcCtD
Crizotinib—Malnutrition—Vemurafenib—melanoma	0.000173	0.00526	CcSEcCtD
Crizotinib—MERTK—eye—melanoma	0.000172	0.00503	CbGeAlD
Crizotinib—MERTK—retina—melanoma	0.000171	0.00499	CbGeAlD
Crizotinib—TYRO3—skin of body—melanoma	0.000171	0.00498	CbGeAlD
Crizotinib—Dysgeusia—Vemurafenib—melanoma	0.000169	0.00515	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Temozolomide—melanoma	0.000168	0.00513	CcSEcCtD
Crizotinib—MAP3K12—eye—melanoma	0.000167	0.00487	CbGeAlD
Crizotinib—ACVR1—eye—melanoma	0.000167	0.00487	CbGeAlD
Crizotinib—DCLK1—mammalian vulva—melanoma	0.000167	0.00487	CbGeAlD
Crizotinib—ACVR1—retina—melanoma	0.000165	0.00483	CbGeAlD
Crizotinib—IGF1R—skin of body—melanoma	0.000164	0.00479	CbGeAlD
Crizotinib—PRKD1—head—melanoma	0.000164	0.00478	CbGeAlD
Crizotinib—Hepatic failure—Temozolomide—melanoma	0.000163	0.00497	CcSEcCtD
Crizotinib—SIK2—head—melanoma	0.000161	0.00472	CbGeAlD
Crizotinib—FER—mammalian vulva—melanoma	0.000156	0.00454	CbGeAlD
Crizotinib—TNK1—mammalian vulva—melanoma	0.000154	0.0045	CbGeAlD
Crizotinib—MAP4K1—mammalian vulva—melanoma	0.000152	0.00445	CbGeAlD
Crizotinib—Diplopia—Carmustine—melanoma	0.000152	0.00462	CcSEcCtD
Crizotinib—RIPK2—eye—melanoma	0.000151	0.0044	CbGeAlD
Crizotinib—LTK—head—melanoma	0.00015	0.00438	CbGeAlD
Crizotinib—RIPK2—retina—melanoma	0.000149	0.00436	CbGeAlD
Crizotinib—Diplopia—Temozolomide—melanoma	0.000147	0.00446	CcSEcCtD
Crizotinib—Face oedema—Carmustine—melanoma	0.000146	0.00446	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000146	0.00445	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000146	0.00444	CcSEcCtD
Crizotinib—MAPK7—head—melanoma	0.000145	0.00425	CbGeAlD
Crizotinib—TXK—head—melanoma	0.000145	0.00425	CbGeAlD
Crizotinib—EPHA8—head—melanoma	0.000144	0.0042	CbGeAlD
Crizotinib—STK35—skin of body—melanoma	0.000142	0.00415	CbGeAlD
Crizotinib—AURKA—mammalian vulva—melanoma	0.000142	0.00414	CbGeAlD
Crizotinib—Face oedema—Temozolomide—melanoma	0.000141	0.00431	CcSEcCtD
Crizotinib—TESK1—mammalian vulva—melanoma	0.000141	0.0041	CbGeAlD
Crizotinib—Infection—Vemurafenib—melanoma	0.00014	0.00426	CcSEcCtD
Crizotinib—TBK1—eye—melanoma	0.00014	0.00408	CbGeAlD
Crizotinib—TYK2—eye—melanoma	0.000139	0.00406	CbGeAlD
Crizotinib—Nervous system disorder—Vemurafenib—melanoma	0.000138	0.00421	CcSEcCtD
Crizotinib—Hypokalaemia—Carmustine—melanoma	0.000138	0.0042	CcSEcCtD
Crizotinib—TYK2—retina—melanoma	0.000138	0.00402	CbGeAlD
Crizotinib—Skin disorder—Vemurafenib—melanoma	0.000137	0.00417	CcSEcCtD
Crizotinib—Respiratory failure—Docetaxel—melanoma	0.000137	0.00416	CcSEcCtD
Crizotinib—MERTK—mammalian vulva—melanoma	0.000137	0.00399	CbGeAlD
Crizotinib—MET—head—melanoma	0.000136	0.00397	CbGeAlD
Crizotinib—Weight decreased—Bleomycin—melanoma	0.000136	0.00414	CcSEcCtD
Crizotinib—Pneumonia—Bleomycin—melanoma	0.000135	0.0041	CcSEcCtD
Crizotinib—RPS6KB1—eye—melanoma	0.000135	0.00393	CbGeAlD
Crizotinib—Pulmonary embolism—Docetaxel—melanoma	0.000134	0.00409	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Docetaxel—melanoma	0.000134	0.00409	CcSEcCtD
Crizotinib—Muscular weakness—Carmustine—melanoma	0.000134	0.00407	CcSEcCtD
Crizotinib—LIMK2—mammalian vulva—melanoma	0.000134	0.00391	CbGeAlD
Crizotinib—Hypokalaemia—Temozolomide—melanoma	0.000133	0.00406	CcSEcCtD
Crizotinib—RPS6KB1—retina—melanoma	0.000133	0.00389	CbGeAlD
Crizotinib—NUAK2—mammalian vulva—melanoma	0.000133	0.00389	CbGeAlD
Crizotinib—AXL—eye—melanoma	0.000133	0.00389	CbGeAlD
Crizotinib—MAP3K12—mammalian vulva—melanoma	0.000132	0.00386	CbGeAlD
Crizotinib—ACVR1—mammalian vulva—melanoma	0.000132	0.00386	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000132	0.00402	CcSEcCtD
Crizotinib—AXL—retina—melanoma	0.000132	0.00385	CbGeAlD
Crizotinib—CDK7—head—melanoma	0.000132	0.00384	CbGeAlD
Crizotinib—RIPK2—skin of body—melanoma	0.000131	0.00383	CbGeAlD
Crizotinib—Neutropenia—Dactinomycin—melanoma	0.000131	0.00399	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000129	0.00394	CcSEcCtD
Crizotinib—Muscular weakness—Temozolomide—melanoma	0.000129	0.00394	CcSEcCtD
Crizotinib—Fluid retention—Docetaxel—melanoma	0.000127	0.00388	CcSEcCtD
Crizotinib—Neuropathy—Docetaxel—melanoma	0.000126	0.00384	CcSEcCtD
Crizotinib—EPHA3—head—melanoma	0.000126	0.00367	CbGeAlD
Crizotinib—ACVR1B—head—melanoma	0.000126	0.00367	CbGeAlD
Crizotinib—NEK9—lymph node—melanoma	0.000126	0.00367	CbGeAlD
Crizotinib—Pneumonia—Dactinomycin—melanoma	0.000126	0.00383	CcSEcCtD
Crizotinib—Neutropenia—Carmustine—melanoma	0.000123	0.00373	CcSEcCtD
Crizotinib—Decreased appetite—Vemurafenib—melanoma	0.000123	0.00373	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000122	0.00371	CcSEcCtD
Crizotinib—PTK2—skin of body—melanoma	0.000122	0.00355	CbGeAlD
Crizotinib—Fatigue—Vemurafenib—melanoma	0.000122	0.0037	CcSEcCtD
Crizotinib—TYK2—skin of body—melanoma	0.000121	0.00353	CbGeAlD
Crizotinib—Constipation—Vemurafenib—melanoma	0.000121	0.00367	CcSEcCtD
Crizotinib—JAK3—head—melanoma	0.00012	0.0035	CbGeAlD
Crizotinib—EPHA6—head—melanoma	0.00012	0.0035	CbGeAlD
Crizotinib—Hypoaesthesia—Bleomycin—melanoma	0.00012	0.00364	CcSEcCtD
Crizotinib—DCLK1—head—melanoma	0.000119	0.00348	CbGeAlD
Crizotinib—Neutropenia—Temozolomide—melanoma	0.000118	0.00361	CcSEcCtD
Crizotinib—STK4—head—melanoma	0.000118	0.00344	CbGeAlD
Crizotinib—Upper respiratory tract infection—Temozolomide—melanoma	0.000118	0.00359	CcSEcCtD
Crizotinib—Pneumonia—Carmustine—melanoma	0.000118	0.00358	CcSEcCtD
Crizotinib—Sepsis—Docetaxel—melanoma	0.000117	0.00355	CcSEcCtD
Crizotinib—AXL—skin of body—melanoma	0.000116	0.00338	CbGeAlD
Crizotinib—EPHA4—mammalian vulva—melanoma	0.000116	0.00337	CbGeAlD
Crizotinib—Weight decreased—Temozolomide—melanoma	0.000115	0.00349	CcSEcCtD
Crizotinib—PRKD1—lymph node—melanoma	0.000115	0.00335	CbGeAlD
Crizotinib—Neuropathy peripheral—Carmustine—melanoma	0.000115	0.00349	CcSEcCtD
Crizotinib—Pneumonia—Temozolomide—melanoma	0.000114	0.00346	CcSEcCtD
Crizotinib—LIMK1—lymph node—melanoma	0.000113	0.0033	CbGeAlD
Crizotinib—Infestation—Temozolomide—melanoma	0.000113	0.00344	CcSEcCtD
Crizotinib—Infestation NOS—Temozolomide—melanoma	0.000113	0.00344	CcSEcCtD
Crizotinib—YES1—eye—melanoma	0.000112	0.00329	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.000112	0.00341	CcSEcCtD
Crizotinib—YES1—retina—melanoma	0.000111	0.00326	CbGeAlD
Crizotinib—Body temperature increased—Vemurafenib—melanoma	0.000111	0.00339	CcSEcCtD
Crizotinib—TYRO3—head—melanoma	0.000111	0.00325	CbGeAlD
Crizotinib—FER—head—melanoma	0.000111	0.00325	CbGeAlD
Crizotinib—ALK—head—melanoma	0.000111	0.00325	CbGeAlD
Crizotinib—EPHA5—head—melanoma	0.000111	0.00325	CbGeAlD
Crizotinib—TAOK3—eye—melanoma	0.000111	0.00324	CbGeAlD
Crizotinib—TBK1—mammalian vulva—melanoma	0.000111	0.00324	CbGeAlD
Crizotinib—LYN—head—melanoma	0.000111	0.00323	CbGeAlD
Crizotinib—Neuropathy peripheral—Temozolomide—melanoma	0.000111	0.00337	CcSEcCtD
Crizotinib—TYK2—mammalian vulva—melanoma	0.00011	0.00322	CbGeAlD
Crizotinib—PRKD3—lymph node—melanoma	0.00011	0.00322	CbGeAlD
Crizotinib—TAOK3—retina—melanoma	0.00011	0.00321	CbGeAlD
Crizotinib—JAK2—skin of body—melanoma	0.00011	0.00321	CbGeAlD
Crizotinib—BMPR1B—head—melanoma	0.000109	0.00319	CbGeAlD
Crizotinib—MAP3K19—head—melanoma	0.000109	0.00319	CbGeAlD
Crizotinib—IRAK1—mammalian vulva—melanoma	0.000109	0.00318	CbGeAlD
Crizotinib—Hepatic failure—Docetaxel—melanoma	0.000108	0.0033	CcSEcCtD
Crizotinib—SRC—eye—melanoma	0.000108	0.00316	CbGeAlD
Crizotinib—DSTYK—lymph node—melanoma	0.000108	0.00314	CbGeAlD
Crizotinib—SRC—retina—melanoma	0.000107	0.00313	CbGeAlD
Crizotinib—IGF1R—head—melanoma	0.000107	0.00312	CbGeAlD
Crizotinib—TNK2—head—melanoma	0.000107	0.00312	CbGeAlD
Crizotinib—Hepatobiliary disease—Temozolomide—melanoma	0.000107	0.00325	CcSEcCtD
Crizotinib—RPS6KB1—mammalian vulva—melanoma	0.000107	0.00312	CbGeAlD
Crizotinib—BLK—lymph node—melanoma	0.000106	0.0031	CbGeAlD
Crizotinib—LCK—mammalian vulva—melanoma	0.000106	0.0031	CbGeAlD
Crizotinib—FGR—mammalian vulva—melanoma	0.000106	0.0031	CbGeAlD
Crizotinib—MAP3K3—skin of body—melanoma	0.000106	0.00309	CbGeAlD
Crizotinib—AXL—mammalian vulva—melanoma	0.000106	0.00309	CbGeAlD
Crizotinib—LTK—lymph node—melanoma	0.000105	0.00307	CbGeAlD
Crizotinib—CASK—lymph node—melanoma	0.000105	0.00307	CbGeAlD
Crizotinib—Hypoaesthesia—Carmustine—melanoma	0.000104	0.00318	CcSEcCtD
Crizotinib—STK3—head—melanoma	0.000104	0.00304	CbGeAlD
Crizotinib—TIE1—head—melanoma	0.000104	0.00304	CbGeAlD
Crizotinib—Oedema peripheral—Carmustine—melanoma	0.000103	0.00315	CcSEcCtD
Crizotinib—Visual disturbance—Docetaxel—melanoma	0.000103	0.00313	CcSEcCtD
Crizotinib—MAPK7—lymph node—melanoma	0.000102	0.00297	CbGeAlD
Crizotinib—TXK—lymph node—melanoma	0.000102	0.00297	CbGeAlD
Crizotinib—SLK—mammalian vulva—melanoma	0.000102	0.00297	CbGeAlD
Crizotinib—AURKA—head—melanoma	0.000101	0.00296	CbGeAlD
Crizotinib—EPHB6—skin of body—melanoma	0.000101	0.00296	CbGeAlD
Crizotinib—Asthenia—Vemurafenib—melanoma	0.000101	0.00308	CcSEcCtD
Crizotinib—Visual impairment—Carmustine—melanoma	0.000101	0.00308	CcSEcCtD
Crizotinib—EPHB4—mammalian vulva—melanoma	0.000101	0.00295	CbGeAlD
Crizotinib—Hypoaesthesia—Temozolomide—melanoma	0.000101	0.00307	CcSEcCtD
Crizotinib—FES—lymph node—melanoma	0.000101	0.00294	CbGeAlD
Crizotinib—TESK1—head—melanoma	0.000101	0.00294	CbGeAlD
Crizotinib—JAK2—mammalian vulva—melanoma	0.0001	0.00293	CbGeAlD
Crizotinib—Urinary tract disorder—Temozolomide—melanoma	0.0001	0.00305	CcSEcCtD
Crizotinib—Oedema peripheral—Temozolomide—melanoma	9.99e-05	0.00304	CcSEcCtD
Crizotinib—Urethral disorder—Temozolomide—melanoma	9.94e-05	0.00303	CcSEcCtD
Crizotinib—EPHA2—mammalian vulva—melanoma	9.91e-05	0.00289	CbGeAlD
Crizotinib—Eye disorder—Carmustine—melanoma	9.8e-05	0.00299	CcSEcCtD
Crizotinib—MERTK—head—melanoma	9.78e-05	0.00286	CbGeAlD
Crizotinib—Visual impairment—Temozolomide—melanoma	9.77e-05	0.00298	CcSEcCtD
Crizotinib—CSF1R—eye—melanoma	9.71e-05	0.00284	CbGeAlD
Crizotinib—Anaemia—Bleomycin—melanoma	9.67e-05	0.00295	CcSEcCtD
Crizotinib—MAP3K3—mammalian vulva—melanoma	9.66e-05	0.00282	CbGeAlD
Crizotinib—MAP4K5—mammalian vulva—melanoma	9.66e-05	0.00282	CbGeAlD
Crizotinib—Diarrhoea—Vemurafenib—melanoma	9.64e-05	0.00294	CcSEcCtD
Crizotinib—LIMK2—head—melanoma	9.57e-05	0.00279	CbGeAlD
Crizotinib—MET—lymph node—melanoma	9.53e-05	0.00278	CbGeAlD
Crizotinib—Eye disorder—Temozolomide—melanoma	9.47e-05	0.00289	CcSEcCtD
Crizotinib—MAP3K12—head—melanoma	9.46e-05	0.00276	CbGeAlD
Crizotinib—ACVR1—head—melanoma	9.46e-05	0.00276	CbGeAlD
Crizotinib—SRC—skin of body—melanoma	9.41e-05	0.00275	CbGeAlD
Crizotinib—Cardiac disorder—Temozolomide—melanoma	9.41e-05	0.00287	CcSEcCtD
Crizotinib—Arrhythmia—Carmustine—melanoma	9.37e-05	0.00285	CcSEcCtD
Crizotinib—Leukopenia—Bleomycin—melanoma	9.37e-05	0.00285	CcSEcCtD
Crizotinib—Dizziness—Vemurafenib—melanoma	9.32e-05	0.00284	CcSEcCtD
Crizotinib—STK35—head—melanoma	9.27e-05	0.00271	CbGeAlD
Crizotinib—EPHB6—mammalian vulva—melanoma	9.23e-05	0.0027	CbGeAlD
Crizotinib—CDK7—lymph node—melanoma	9.22e-05	0.00269	CbGeAlD
Crizotinib—TAOK2—lymph node—melanoma	9.14e-05	0.00267	CbGeAlD
Crizotinib—Mediastinal disorder—Temozolomide—melanoma	9.14e-05	0.00278	CcSEcCtD
Crizotinib—Malnutrition—Carmustine—melanoma	9.13e-05	0.00278	CcSEcCtD
Crizotinib—Anaemia—Dactinomycin—melanoma	9.02e-05	0.00275	CcSEcCtD
Crizotinib—Vomiting—Vemurafenib—melanoma	8.96e-05	0.00273	CcSEcCtD
Crizotinib—BMP2K—head—melanoma	8.93e-05	0.00261	CbGeAlD
Crizotinib—YES1—mammalian vulva—melanoma	8.92e-05	0.00261	CbGeAlD
Crizotinib—Rash—Vemurafenib—melanoma	8.89e-05	0.00271	CcSEcCtD
Crizotinib—Dermatitis—Vemurafenib—melanoma	8.88e-05	0.0027	CcSEcCtD
Crizotinib—STK10—mammalian vulva—melanoma	8.84e-05	0.00258	CbGeAlD
Crizotinib—Malnutrition—Temozolomide—melanoma	8.83e-05	0.00269	CcSEcCtD
Crizotinib—TAOK3—mammalian vulva—melanoma	8.81e-05	0.00257	CbGeAlD
Crizotinib—EPHA3—lymph node—melanoma	8.81e-05	0.00257	CbGeAlD
Crizotinib—ACVR1B—lymph node—melanoma	8.81e-05	0.00257	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Docetaxel—melanoma	8.78e-05	0.00267	CcSEcCtD
Crizotinib—Leukopenia—Dactinomycin—melanoma	8.73e-05	0.00266	CcSEcCtD
Crizotinib—Dysgeusia—Temozolomide—melanoma	8.64e-05	0.00263	CcSEcCtD
Crizotinib—PTK2B—head—melanoma	8.62e-05	0.00252	CbGeAlD
Crizotinib—Vision blurred—Carmustine—melanoma	8.61e-05	0.00262	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Docetaxel—melanoma	8.6e-05	0.00262	CcSEcCtD
Crizotinib—RIPK2—head—melanoma	8.55e-05	0.0025	CbGeAlD
Crizotinib—Oedema—Bleomycin—melanoma	8.54e-05	0.0026	CcSEcCtD
Crizotinib—Infection—Bleomycin—melanoma	8.48e-05	0.00258	CcSEcCtD
Crizotinib—CSF1R—skin of body—melanoma	8.45e-05	0.00247	CbGeAlD
Crizotinib—Anaemia—Carmustine—melanoma	8.44e-05	0.00257	CcSEcCtD
Crizotinib—JAK3—lymph node—melanoma	8.4e-05	0.00245	CbGeAlD
Crizotinib—Nausea—Vemurafenib—melanoma	8.37e-05	0.00255	CcSEcCtD
Crizotinib—DCLK1—lymph node—melanoma	8.35e-05	0.00244	CbGeAlD
Crizotinib—Vision blurred—Temozolomide—melanoma	8.32e-05	0.00253	CcSEcCtD
Crizotinib—PLK4—lymph node—melanoma	8.3e-05	0.00242	CbGeAlD
Crizotinib—EPHA4—head—melanoma	8.26e-05	0.00241	CbGeAlD
Crizotinib—STK4—lymph node—melanoma	8.25e-05	0.00241	CbGeAlD
Crizotinib—Leukopenia—Carmustine—melanoma	8.18e-05	0.00249	CcSEcCtD
Crizotinib—Anaemia—Temozolomide—melanoma	8.16e-05	0.00248	CcSEcCtD
Crizotinib—MAP3K2—head—melanoma	8.1e-05	0.00237	CbGeAlD
Crizotinib—Oedema—Dactinomycin—melanoma	7.96e-05	0.00243	CcSEcCtD
Crizotinib—TBK1—head—melanoma	7.94e-05	0.00232	CbGeAlD
Crizotinib—PTK2—head—melanoma	7.94e-05	0.00232	CbGeAlD
Crizotinib—Infection—Dactinomycin—melanoma	7.91e-05	0.00241	CcSEcCtD
Crizotinib—Leukopenia—Temozolomide—melanoma	7.9e-05	0.00241	CcSEcCtD
Crizotinib—TYK2—head—melanoma	7.88e-05	0.0023	CbGeAlD
Crizotinib—Neutropenia—Docetaxel—melanoma	7.88e-05	0.0024	CcSEcCtD
Crizotinib—FER—lymph node—melanoma	7.79e-05	0.00228	CbGeAlD
Crizotinib—ALK—lymph node—melanoma	7.79e-05	0.00228	CbGeAlD
Crizotinib—TNK1—lymph node—melanoma	7.71e-05	0.00225	CbGeAlD
Crizotinib—CSF1R—mammalian vulva—melanoma	7.71e-05	0.00225	CbGeAlD
Crizotinib—ABL1—eye—melanoma	7.68e-05	0.00224	CbGeAlD
Crizotinib—Paraesthesia—Bleomycin—melanoma	7.67e-05	0.00234	CcSEcCtD
Crizotinib—BMPR1B—lymph node—melanoma	7.64e-05	0.00223	CbGeAlD
Crizotinib—MAP4K1—lymph node—melanoma	7.64e-05	0.00223	CbGeAlD
Crizotinib—RPS6KB1—head—melanoma	7.64e-05	0.00223	CbGeAlD
Crizotinib—Weight decreased—Docetaxel—melanoma	7.62e-05	0.00232	CcSEcCtD
Crizotinib—Dyspnoea—Bleomycin—melanoma	7.61e-05	0.00232	CcSEcCtD
Crizotinib—ABL1—retina—melanoma	7.61e-05	0.00222	CbGeAlD
Crizotinib—FGR—head—melanoma	7.59e-05	0.00222	CbGeAlD
Crizotinib—AXL—head—melanoma	7.56e-05	0.00221	CbGeAlD
Crizotinib—Pneumonia—Docetaxel—melanoma	7.55e-05	0.0023	CcSEcCtD
Crizotinib—Infestation—Docetaxel—melanoma	7.51e-05	0.00229	CcSEcCtD
Crizotinib—Infestation NOS—Docetaxel—melanoma	7.51e-05	0.00229	CcSEcCtD
Crizotinib—IGF1R—lymph node—melanoma	7.49e-05	0.00219	CbGeAlD
Crizotinib—TNK2—lymph node—melanoma	7.49e-05	0.00219	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	7.46e-05	0.00227	CcSEcCtD
Crizotinib—Oedema—Carmustine—melanoma	7.45e-05	0.00227	CcSEcCtD
Crizotinib—Decreased appetite—Bleomycin—melanoma	7.42e-05	0.00226	CcSEcCtD
Crizotinib—Infection—Carmustine—melanoma	7.41e-05	0.00226	CcSEcCtD
Crizotinib—MAP4K2—lymph node—melanoma	7.38e-05	0.00216	CbGeAlD
Crizotinib—Neuropathy peripheral—Docetaxel—melanoma	7.36e-05	0.00224	CcSEcCtD
Crizotinib—TIE1—lymph node—melanoma	7.28e-05	0.00213	CbGeAlD
Crizotinib—STK3—lymph node—melanoma	7.28e-05	0.00213	CbGeAlD
Crizotinib—Oedema—Temozolomide—melanoma	7.2e-05	0.00219	CcSEcCtD
Crizotinib—JAK2—head—melanoma	7.17e-05	0.00209	CbGeAlD
Crizotinib—Infection—Temozolomide—melanoma	7.16e-05	0.00218	CcSEcCtD
Crizotinib—Hepatobiliary disease—Docetaxel—melanoma	7.1e-05	0.00216	CcSEcCtD
Crizotinib—AURKA—lymph node—melanoma	7.1e-05	0.00207	CbGeAlD
Crizotinib—EPHA2—head—melanoma	7.09e-05	0.00207	CbGeAlD
Crizotinib—Nervous system disorder—Temozolomide—melanoma	7.06e-05	0.00215	CcSEcCtD
Crizotinib—TESK1—lymph node—melanoma	7.04e-05	0.00206	CbGeAlD
Crizotinib—Skin disorder—Temozolomide—melanoma	7e-05	0.00213	CcSEcCtD
Crizotinib—Decreased appetite—Dactinomycin—melanoma	6.92e-05	0.00211	CcSEcCtD
Crizotinib—MAP4K5—head—melanoma	6.91e-05	0.00202	CbGeAlD
Crizotinib—TEK—head—melanoma	6.91e-05	0.00202	CbGeAlD
Crizotinib—MAP3K3—head—melanoma	6.91e-05	0.00202	CbGeAlD
Crizotinib—Fatigue—Dactinomycin—melanoma	6.87e-05	0.00209	CcSEcCtD
Crizotinib—MERTK—lymph node—melanoma	6.85e-05	0.002	CbGeAlD
Crizotinib—Body temperature increased—Bleomycin—melanoma	6.75e-05	0.00206	CcSEcCtD
Crizotinib—Hypoaesthesia—Docetaxel—melanoma	6.71e-05	0.00204	CcSEcCtD
Crizotinib—LIMK2—lymph node—melanoma	6.7e-05	0.00196	CbGeAlD
Crizotinib—Paraesthesia—Carmustine—melanoma	6.69e-05	0.00204	CcSEcCtD
Crizotinib—ABL1—skin of body—melanoma	6.68e-05	0.00195	CbGeAlD
Crizotinib—NUAK2—lymph node—melanoma	6.67e-05	0.00195	CbGeAlD
Crizotinib—Urinary tract disorder—Docetaxel—melanoma	6.66e-05	0.00203	CcSEcCtD
Crizotinib—Dyspnoea—Carmustine—melanoma	6.65e-05	0.00202	CcSEcCtD
Crizotinib—Oedema peripheral—Docetaxel—melanoma	6.64e-05	0.00202	CcSEcCtD
Crizotinib—ACVR1—lymph node—melanoma	6.63e-05	0.00194	CbGeAlD
Crizotinib—MAP3K12—lymph node—melanoma	6.63e-05	0.00194	CbGeAlD
Crizotinib—FLT3—lymph node—melanoma	6.63e-05	0.00194	CbGeAlD
Crizotinib—Urethral disorder—Docetaxel—melanoma	6.61e-05	0.00201	CcSEcCtD
Crizotinib—EPHB6—head—melanoma	6.61e-05	0.00193	CbGeAlD
Crizotinib—Visual impairment—Docetaxel—melanoma	6.5e-05	0.00198	CcSEcCtD
Crizotinib—STK35—lymph node—melanoma	6.49e-05	0.0019	CbGeAlD
Crizotinib—Decreased appetite—Carmustine—melanoma	6.48e-05	0.00197	CcSEcCtD
Crizotinib—Paraesthesia—Temozolomide—melanoma	6.47e-05	0.00197	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Carmustine—melanoma	6.44e-05	0.00196	CcSEcCtD
Crizotinib—Dyspnoea—Temozolomide—melanoma	6.42e-05	0.00196	CcSEcCtD
Crizotinib—YES1—head—melanoma	6.38e-05	0.00186	CbGeAlD
Crizotinib—Constipation—Carmustine—melanoma	6.37e-05	0.00194	CcSEcCtD
Crizotinib—Dyspepsia—Temozolomide—melanoma	6.34e-05	0.00193	CcSEcCtD
Crizotinib—ABL2—lymph node—melanoma	6.33e-05	0.00185	CbGeAlD
Crizotinib—STK10—head—melanoma	6.33e-05	0.00185	CbGeAlD
Crizotinib—TAOK3—head—melanoma	6.3e-05	0.00184	CbGeAlD
Crizotinib—Eye disorder—Docetaxel—melanoma	6.3e-05	0.00192	CcSEcCtD
Crizotinib—Body temperature increased—Dactinomycin—melanoma	6.3e-05	0.00192	CcSEcCtD
Crizotinib—Decreased appetite—Temozolomide—melanoma	6.26e-05	0.00191	CcSEcCtD
Crizotinib—Cardiac disorder—Docetaxel—melanoma	6.26e-05	0.00191	CcSEcCtD
Crizotinib—BMP2K—lymph node—melanoma	6.25e-05	0.00183	CbGeAlD
Crizotinib—Gastrointestinal disorder—Temozolomide—melanoma	6.22e-05	0.00189	CcSEcCtD
Crizotinib—Fatigue—Temozolomide—melanoma	6.21e-05	0.00189	CcSEcCtD
Crizotinib—Constipation—Temozolomide—melanoma	6.16e-05	0.00188	CcSEcCtD
Crizotinib—SRC—head—melanoma	6.14e-05	0.00179	CbGeAlD
Crizotinib—Asthenia—Bleomycin—melanoma	6.13e-05	0.00187	CcSEcCtD
Crizotinib—ABL1—mammalian vulva—melanoma	6.09e-05	0.00178	CbGeAlD
Crizotinib—Mediastinal disorder—Docetaxel—melanoma	6.08e-05	0.00185	CcSEcCtD
Crizotinib—PTK2B—lymph node—melanoma	6.04e-05	0.00176	CbGeAlD
Crizotinib—Arrhythmia—Docetaxel—melanoma	6.02e-05	0.00183	CcSEcCtD
Crizotinib—RIPK2—lymph node—melanoma	5.99e-05	0.00175	CbGeAlD
Crizotinib—Body temperature increased—Carmustine—melanoma	5.89e-05	0.00179	CcSEcCtD
Crizotinib—Malnutrition—Docetaxel—melanoma	5.87e-05	0.00179	CcSEcCtD
Crizotinib—EPHA4—lymph node—melanoma	5.79e-05	0.00169	CbGeAlD
Crizotinib—Dysgeusia—Docetaxel—melanoma	5.75e-05	0.00175	CcSEcCtD
Crizotinib—Asthenia—Dactinomycin—melanoma	5.71e-05	0.00174	CcSEcCtD
Crizotinib—Body temperature increased—Temozolomide—melanoma	5.69e-05	0.00173	CcSEcCtD
Crizotinib—MAP3K2—lymph node—melanoma	5.68e-05	0.00166	CbGeAlD
Crizotinib—TBK1—lymph node—melanoma	5.56e-05	0.00162	CbGeAlD
Crizotinib—PTK2—lymph node—melanoma	5.56e-05	0.00162	CbGeAlD
Crizotinib—TYK2—lymph node—melanoma	5.52e-05	0.00161	CbGeAlD
Crizotinib—CSF1R—head—melanoma	5.51e-05	0.00161	CbGeAlD
Crizotinib—Diarrhoea—Dactinomycin—melanoma	5.45e-05	0.00166	CcSEcCtD
Crizotinib—IRAK1—lymph node—melanoma	5.45e-05	0.00159	CbGeAlD
Crizotinib—Vomiting—Bleomycin—melanoma	5.43e-05	0.00165	CcSEcCtD
Crizotinib—Anaemia—Docetaxel—melanoma	5.42e-05	0.00165	CcSEcCtD
Crizotinib—Rash—Bleomycin—melanoma	5.38e-05	0.00164	CcSEcCtD
Crizotinib—Dermatitis—Bleomycin—melanoma	5.38e-05	0.00164	CcSEcCtD
Crizotinib—Asthenia—Carmustine—melanoma	5.35e-05	0.00163	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—melanoma	5.35e-05	0.00156	CbGeAlD
Crizotinib—LCK—lymph node—melanoma	5.31e-05	0.00155	CbGeAlD
Crizotinib—FGR—lymph node—melanoma	5.31e-05	0.00155	CbGeAlD
Crizotinib—AXL—lymph node—melanoma	5.29e-05	0.00155	CbGeAlD
Crizotinib—Syncope—Docetaxel—melanoma	5.26e-05	0.0016	CcSEcCtD
Crizotinib—Leukopenia—Docetaxel—melanoma	5.25e-05	0.0016	CcSEcCtD
Crizotinib—Asthenia—Temozolomide—melanoma	5.17e-05	0.00157	CcSEcCtD
Crizotinib—Loss of consciousness—Docetaxel—melanoma	5.16e-05	0.00157	CcSEcCtD
Crizotinib—Diarrhoea—Carmustine—melanoma	5.1e-05	0.00155	CcSEcCtD
Crizotinib—SLK—lymph node—melanoma	5.09e-05	0.00149	CbGeAlD
Crizotinib—Nausea—Bleomycin—melanoma	5.07e-05	0.00154	CcSEcCtD
Crizotinib—Vomiting—Dactinomycin—melanoma	5.06e-05	0.00154	CcSEcCtD
Crizotinib—EPHB4—lymph node—melanoma	5.06e-05	0.00148	CbGeAlD
Crizotinib—JAK2—lymph node—melanoma	5.02e-05	0.00147	CbGeAlD
Crizotinib—Rash—Dactinomycin—melanoma	5.02e-05	0.00153	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	4.96e-05	0.00151	CcSEcCtD
Crizotinib—EPHA2—lymph node—melanoma	4.96e-05	0.00145	CbGeAlD
Crizotinib—Dizziness—Carmustine—melanoma	4.93e-05	0.0015	CcSEcCtD
Crizotinib—Diarrhoea—Temozolomide—melanoma	4.93e-05	0.0015	CcSEcCtD
Crizotinib—MAP3K3—lymph node—melanoma	4.84e-05	0.00141	CbGeAlD
Crizotinib—TEK—lymph node—melanoma	4.84e-05	0.00141	CbGeAlD
Crizotinib—MAP4K5—lymph node—melanoma	4.84e-05	0.00141	CbGeAlD
Crizotinib—Oedema—Docetaxel—melanoma	4.79e-05	0.00146	CcSEcCtD
Crizotinib—Dizziness—Temozolomide—melanoma	4.76e-05	0.00145	CcSEcCtD
Crizotinib—Infection—Docetaxel—melanoma	4.76e-05	0.00145	CcSEcCtD
Crizotinib—Vomiting—Carmustine—melanoma	4.74e-05	0.00144	CcSEcCtD
Crizotinib—Nausea—Dactinomycin—melanoma	4.73e-05	0.00144	CcSEcCtD
Crizotinib—Shock—Docetaxel—melanoma	4.71e-05	0.00144	CcSEcCtD
Crizotinib—Rash—Carmustine—melanoma	4.7e-05	0.00143	CcSEcCtD
Crizotinib—Nervous system disorder—Docetaxel—melanoma	4.7e-05	0.00143	CcSEcCtD
Crizotinib—Dermatitis—Carmustine—melanoma	4.7e-05	0.00143	CcSEcCtD
Crizotinib—Skin disorder—Docetaxel—melanoma	4.65e-05	0.00142	CcSEcCtD
Crizotinib—EPHB6—lymph node—melanoma	4.63e-05	0.00135	CbGeAlD
Crizotinib—Vomiting—Temozolomide—melanoma	4.58e-05	0.00139	CcSEcCtD
Crizotinib—Rash—Temozolomide—melanoma	4.54e-05	0.00138	CcSEcCtD
Crizotinib—Dermatitis—Temozolomide—melanoma	4.54e-05	0.00138	CcSEcCtD
Crizotinib—ABCB1—blood vessel—melanoma	4.49e-05	0.00131	CbGeAlD
Crizotinib—YES1—lymph node—melanoma	4.47e-05	0.00131	CbGeAlD
Crizotinib—STK10—lymph node—melanoma	4.43e-05	0.00129	CbGeAlD
Crizotinib—Nausea—Carmustine—melanoma	4.43e-05	0.00135	CcSEcCtD
Crizotinib—TAOK3—lymph node—melanoma	4.41e-05	0.00129	CbGeAlD
Crizotinib—ABL1—head—melanoma	4.36e-05	0.00127	CbGeAlD
Crizotinib—Paraesthesia—Docetaxel—melanoma	4.3e-05	0.00131	CcSEcCtD
Crizotinib—SRC—lymph node—melanoma	4.3e-05	0.00126	CbGeAlD
Crizotinib—Nausea—Temozolomide—melanoma	4.28e-05	0.0013	CcSEcCtD
Crizotinib—Dyspnoea—Docetaxel—melanoma	4.27e-05	0.0013	CcSEcCtD
Crizotinib—Dyspepsia—Docetaxel—melanoma	4.22e-05	0.00128	CcSEcCtD
Crizotinib—Decreased appetite—Docetaxel—melanoma	4.16e-05	0.00127	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Docetaxel—melanoma	4.14e-05	0.00126	CcSEcCtD
Crizotinib—Fatigue—Docetaxel—melanoma	4.13e-05	0.00126	CcSEcCtD
Crizotinib—Constipation—Docetaxel—melanoma	4.1e-05	0.00125	CcSEcCtD
Crizotinib—CSF1R—lymph node—melanoma	3.86e-05	0.00113	CbGeAlD
Crizotinib—Body temperature increased—Docetaxel—melanoma	3.79e-05	0.00115	CcSEcCtD
Crizotinib—Asthenia—Docetaxel—melanoma	3.44e-05	0.00105	CcSEcCtD
Crizotinib—Diarrhoea—Docetaxel—melanoma	3.28e-05	0.000998	CcSEcCtD
Crizotinib—Dizziness—Docetaxel—melanoma	3.17e-05	0.000965	CcSEcCtD
Crizotinib—ABL1—lymph node—melanoma	3.05e-05	0.000891	CbGeAlD
Crizotinib—Vomiting—Docetaxel—melanoma	3.05e-05	0.000928	CcSEcCtD
Crizotinib—Rash—Docetaxel—melanoma	3.02e-05	0.00092	CcSEcCtD
Crizotinib—Dermatitis—Docetaxel—melanoma	3.02e-05	0.000919	CcSEcCtD
Crizotinib—Nausea—Docetaxel—melanoma	2.85e-05	0.000867	CcSEcCtD
Crizotinib—ABCB1—retina—melanoma	2.37e-05	0.000691	CbGeAlD
Crizotinib—ABCB1—mammalian vulva—melanoma	1.89e-05	0.000553	CbGeAlD
Crizotinib—ABCB1—head—melanoma	1.36e-05	0.000396	CbGeAlD
Crizotinib—ABCB1—lymph node—melanoma	9.49e-06	0.000277	CbGeAlD
Crizotinib—LYN—Signaling Pathways—CDKN1B—melanoma	1.51e-07	1.8e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGF—melanoma	1.51e-07	1.8e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK3—melanoma	1.51e-07	1.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CB—melanoma	1.51e-07	1.8e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—melanoma	1.51e-07	1.8e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—melanoma	1.51e-07	1.8e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—melanoma	1.49e-07	1.77e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—melanoma	1.49e-07	1.77e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—melanoma	1.49e-07	1.77e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—melanoma	1.48e-07	1.77e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—melanoma	1.48e-07	1.77e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—melanoma	1.48e-07	1.76e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—melanoma	1.47e-07	1.76e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK3—melanoma	1.47e-07	1.75e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—melanoma	1.46e-07	1.74e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—melanoma	1.45e-07	1.73e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—melanoma	1.45e-07	1.73e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF2—melanoma	1.45e-07	1.73e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—melanoma	1.45e-07	1.73e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—melanoma	1.45e-07	1.72e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—melanoma	1.44e-07	1.72e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—melanoma	1.44e-07	1.72e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—melanoma	1.44e-07	1.72e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK1—melanoma	1.44e-07	1.72e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—melanoma	1.44e-07	1.72e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—melanoma	1.44e-07	1.72e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK1—melanoma	1.44e-07	1.71e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—melanoma	1.44e-07	1.71e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—melanoma	1.44e-07	1.71e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—melanoma	1.43e-07	1.71e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—melanoma	1.43e-07	1.71e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—melanoma	1.43e-07	1.7e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—melanoma	1.43e-07	1.7e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—melanoma	1.43e-07	1.7e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—melanoma	1.42e-07	1.7e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—melanoma	1.42e-07	1.7e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—melanoma	1.42e-07	1.69e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—melanoma	1.42e-07	1.69e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—melanoma	1.41e-07	1.68e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—melanoma	1.4e-07	1.67e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—melanoma	1.4e-07	1.67e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—melanoma	1.4e-07	1.67e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK1—melanoma	1.4e-07	1.67e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—melanoma	1.4e-07	1.67e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—melanoma	1.4e-07	1.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—melanoma	1.4e-07	1.67e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—melanoma	1.4e-07	1.66e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—melanoma	1.4e-07	1.66e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK3—melanoma	1.39e-07	1.66e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—melanoma	1.39e-07	1.66e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—melanoma	1.39e-07	1.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—melanoma	1.39e-07	1.65e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NFKB1—melanoma	1.39e-07	1.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—melanoma	1.39e-07	1.65e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—melanoma	1.38e-07	1.65e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—melanoma	1.38e-07	1.64e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PRKCA—melanoma	1.38e-07	1.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—melanoma	1.38e-07	1.64e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—melanoma	1.37e-07	1.63e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ERCC2—melanoma	1.37e-07	1.63e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—melanoma	1.36e-07	1.62e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—melanoma	1.36e-07	1.62e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—melanoma	1.36e-07	1.62e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—melanoma	1.36e-07	1.62e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAP2K1—melanoma	1.35e-07	1.61e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—melanoma	1.35e-07	1.61e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—melanoma	1.35e-07	1.6e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—melanoma	1.34e-07	1.6e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—melanoma	1.34e-07	1.6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—melanoma	1.34e-07	1.6e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—melanoma	1.34e-07	1.59e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—melanoma	1.34e-07	1.59e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK3—melanoma	1.34e-07	1.59e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP17A1—melanoma	1.33e-07	1.59e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK1—melanoma	1.33e-07	1.58e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—melanoma	1.33e-07	1.58e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—melanoma	1.32e-07	1.58e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—melanoma	1.32e-07	1.57e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—melanoma	1.32e-07	1.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—melanoma	1.32e-07	1.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—melanoma	1.31e-07	1.57e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—melanoma	1.31e-07	1.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—melanoma	1.31e-07	1.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—melanoma	1.31e-07	1.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—melanoma	1.3e-07	1.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NFKB1—melanoma	1.3e-07	1.55e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—melanoma	1.29e-07	1.54e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—melanoma	1.29e-07	1.54e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—melanoma	1.29e-07	1.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF2—melanoma	1.29e-07	1.53e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—melanoma	1.28e-07	1.52e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—melanoma	1.27e-07	1.52e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—melanoma	1.27e-07	1.52e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK1—melanoma	1.27e-07	1.52e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—melanoma	1.27e-07	1.51e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—melanoma	1.27e-07	1.51e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—melanoma	1.26e-07	1.5e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—melanoma	1.26e-07	1.5e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—melanoma	1.26e-07	1.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNA11—melanoma	1.26e-07	1.5e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—melanoma	1.25e-07	1.49e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—melanoma	1.25e-07	1.49e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—melanoma	1.25e-07	1.49e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—melanoma	1.25e-07	1.49e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—melanoma	1.24e-07	1.48e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—melanoma	1.24e-07	1.48e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—melanoma	1.24e-07	1.48e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—melanoma	1.24e-07	1.48e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—melanoma	1.24e-07	1.47e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—melanoma	1.24e-07	1.47e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK3—melanoma	1.23e-07	1.47e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—FASN—melanoma	1.23e-07	1.47e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—melanoma	1.22e-07	1.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—melanoma	1.22e-07	1.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—melanoma	1.22e-07	1.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—melanoma	1.21e-07	1.45e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—melanoma	1.21e-07	1.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—melanoma	1.21e-07	1.44e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—melanoma	1.21e-07	1.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—melanoma	1.2e-07	1.43e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—melanoma	1.2e-07	1.43e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—melanoma	1.2e-07	1.43e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK3—melanoma	1.19e-07	1.42e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—melanoma	1.19e-07	1.41e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—melanoma	1.18e-07	1.41e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—melanoma	1.18e-07	1.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—melanoma	1.18e-07	1.4e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—melanoma	1.17e-07	1.4e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK1—melanoma	1.17e-07	1.4e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—melanoma	1.17e-07	1.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—melanoma	1.17e-07	1.4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—melanoma	1.17e-07	1.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNAQ—melanoma	1.17e-07	1.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CD44—melanoma	1.17e-07	1.39e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—melanoma	1.17e-07	1.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—melanoma	1.17e-07	1.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—melanoma	1.16e-07	1.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—melanoma	1.16e-07	1.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—melanoma	1.16e-07	1.39e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—melanoma	1.16e-07	1.38e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—melanoma	1.16e-07	1.38e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—melanoma	1.15e-07	1.37e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—melanoma	1.15e-07	1.37e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—melanoma	1.15e-07	1.37e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—melanoma	1.14e-07	1.36e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—melanoma	1.14e-07	1.36e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NFKB1—melanoma	1.14e-07	1.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK1—melanoma	1.13e-07	1.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—melanoma	1.13e-07	1.35e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—melanoma	1.12e-07	1.34e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—melanoma	1.12e-07	1.34e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1B1—melanoma	1.12e-07	1.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK3—melanoma	1.11e-07	1.33e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—melanoma	1.11e-07	1.32e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—melanoma	1.11e-07	1.32e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—melanoma	1.1e-07	1.32e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—melanoma	1.1e-07	1.31e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—melanoma	1.1e-07	1.31e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—melanoma	1.1e-07	1.31e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—melanoma	1.09e-07	1.3e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—melanoma	1.09e-07	1.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—melanoma	1.08e-07	1.29e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—melanoma	1.08e-07	1.29e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—melanoma	1.08e-07	1.28e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—melanoma	1.08e-07	1.28e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—melanoma	1.07e-07	1.28e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—melanoma	1.07e-07	1.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—melanoma	1.07e-07	1.28e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—melanoma	1.07e-07	1.28e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—melanoma	1.06e-07	1.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK1—melanoma	1.06e-07	1.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—melanoma	1.06e-07	1.26e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—melanoma	1.05e-07	1.25e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—melanoma	1.04e-07	1.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—melanoma	1.04e-07	1.24e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—melanoma	1.03e-07	1.23e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—melanoma	1.02e-07	1.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—melanoma	1.02e-07	1.22e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—melanoma	1.02e-07	1.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—melanoma	1.02e-07	1.21e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—melanoma	1.02e-07	1.21e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—melanoma	1.02e-07	1.21e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—melanoma	1.02e-07	1.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—melanoma	1.02e-07	1.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—melanoma	1.01e-07	1.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—melanoma	1.01e-07	1.2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NFKB1—melanoma	1.01e-07	1.2e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—melanoma	1e-07	1.19e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—melanoma	9.91e-08	1.18e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—melanoma	9.83e-08	1.17e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—melanoma	9.77e-08	1.16e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK3—melanoma	9.76e-08	1.16e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—melanoma	9.51e-08	1.13e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—melanoma	9.5e-08	1.13e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—melanoma	9.49e-08	1.13e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—melanoma	9.48e-08	1.13e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—melanoma	9.42e-08	1.12e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—melanoma	9.4e-08	1.12e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—melanoma	9.38e-08	1.12e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK1—melanoma	9.28e-08	1.11e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—melanoma	9.28e-08	1.11e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—melanoma	9.23e-08	1.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—melanoma	9.2e-08	1.1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—melanoma	9.13e-08	1.09e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—melanoma	9.09e-08	1.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—melanoma	9.04e-08	1.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—melanoma	9.02e-08	1.07e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—melanoma	9.02e-08	1.07e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—melanoma	9.01e-08	1.07e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—melanoma	8.9e-08	1.06e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—melanoma	8.77e-08	1.05e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—melanoma	8.7e-08	1.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK3—melanoma	8.64e-08	1.03e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—melanoma	8.51e-08	1.01e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PRKCA—melanoma	8.5e-08	1.01e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ERCC2—melanoma	8.43e-08	1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—melanoma	8.4e-08	1e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—melanoma	8.32e-08	9.92e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—melanoma	8.28e-08	9.87e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK1—melanoma	8.22e-08	9.8e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—melanoma	8.22e-08	9.79e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—melanoma	8.2e-08	9.78e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—melanoma	8.14e-08	9.71e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—melanoma	8.06e-08	9.6e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—melanoma	8.03e-08	9.57e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—melanoma	7.79e-08	9.29e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—melanoma	7.76e-08	9.25e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—melanoma	7.51e-08	8.96e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—melanoma	7.45e-08	8.88e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—melanoma	7.15e-08	8.53e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—melanoma	7.13e-08	8.5e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—melanoma	7.13e-08	8.5e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—melanoma	6.9e-08	8.22e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—melanoma	6.69e-08	7.97e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—melanoma	6.66e-08	7.93e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—melanoma	6.6e-08	7.86e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—melanoma	6.58e-08	7.84e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—melanoma	6.42e-08	7.66e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—melanoma	6.32e-08	7.53e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—melanoma	5.85e-08	6.97e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—melanoma	5.83e-08	6.94e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—melanoma	5.78e-08	6.88e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—melanoma	5.46e-08	6.51e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—melanoma	5.1e-08	6.08e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—melanoma	5.05e-08	6.02e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—melanoma	5.05e-08	6.01e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—melanoma	4.41e-08	5.25e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—melanoma	4.12e-08	4.91e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—melanoma	3.11e-08	3.71e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—melanoma	2.54e-08	3.03e-07	CbGpPWpGaD
